Physician profile
Rodolfo E Reni
NPI 1619935277
$473.30
in general payments reported to CMS, 2019-2025
9 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $36.06 · 2022: $31.79 · 2023: $87.86 · 2024: $86.90 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $279.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $208.86 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Indivior INC. | $72.15 | 2019-2024 | Perseris |
| Alkermes, INC. | $40.36 | 2020-2025 | Aristada, Aristada Initio |
| Vanda Pharmaceuticals INC. | $37.50 | 2019-2025 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $36.61 | 2019-2025 | Uzedy |
| Allergan, INC. | $25.56 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $20.65 | 2019 | |
| Neurocrine Biosciences, INC. | $17.99 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.62 | 2025 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodolfo Reni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.